About Proteomics International
Proteomics International is a company based in Perth (Australia) founded in 2001 by Richard Lipscombe. Proteomics International offers products and services including PromarkerD, PromarkerEndo, PromarkerEso, and OxiDx. Proteomics International operates in a competitive market with competitors including Metabolon, Maze Therapeutics, Alector, Seer and Tango Therapeutics, among others.
- Headquarter Perth, Australia
- Founders Richard Lipscombe
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website proteomics.com.au
- Social LinkedIn X
- Legal Name Proteomics International Laboratories Ltd
- Annual Revenue$191.47 K (USD)-52.67as on Jun 30, 2026
- Net Profit-$5.9 M (USD)-5.48as on Jun 30, 2026
- EBITDA-$7.63 M (USD)-6.83as on Jun 30, 2026
- Latest Funding Round$4.28M (USD), Post-IPO
Jan 2024
- Investors
Products & Services of Proteomics International
Proteomics International offers a comprehensive portfolio of products and services, including PromarkerD, PromarkerEndo, PromarkerEso, and OxiDx.
Predictive test for diabetic kidney disease detection
Blood test for endometriosis diagnosis accuracy
Esophageal cancer diagnostic with high accuracy
Tool for oxidative stress analysis in health research
Funding Insights of Proteomics International
- Total Rounds 8
- Last Round Post-IPO — $4.28M
- First Round $1M
(Jul 2012)
- Investors Count 1
All 8 funding rounds of Proteomics International with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2024 | $4.28M | Post-IPO | – | – | – |
| Aug 2022 | $5.7M | Post-IPO | – | – | – |
| May 2022 | $413,516 | Grant | – | – | |
| Nov 2021 | $74,632 | Grant | – | – | – |
| Nov 2019 | $2.04M | Post-IPO | – | – | – |
| Dec 2016 | $574,500 | Post-IPO | – | – | – |
| Dec 2016 | $1.44M | Post-IPO | – | – | – |
| Jul 2012 | $1M | Grant | – | – | – |
1 investors in total: 1 institutional.
Investors in Proteomics International
Proteomics International has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include MTPConnect.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Australia's life sciences innovation is accelerated by MTPConnect. | – | mtpconnect.org.au | Australia |
Investor details for Proteomics International
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Proteomics International
14 people are tracked at Proteomics International (5 in leadership, 4 in board & advisors, 5 in team).
| Name | Role | Group |
|---|---|---|
Richard Lipscombe | Co-Founder & Managing Director | Leadership |
Chuck Morrison | Head of Business Development | Leadership |
Scott Bringans | Head of Research | Leadership |
Kirsten Peters | Head of Clinical Studies | Leadership |
Jacqueline Gray | Head Of Corporate Development & CFO | Leadership |
Karen Logan | Company Secretary | Board & advisors |
Roger Moore | Board Member | Board & advisors |
Paul House | Board Member | Board & advisors |
Robyn Elliott | Non-Executive Director | Board & advisors |
Neville Gardiner | Non-Executive Chairman | Team |
Sreeja Sony | Business Manager, Analytical Services | Team |
Catherine Wingate | Product Manager - Promarkerendo | Team |
Mitchell G. Nye-Wood | Proteomics Specialist | Team |
Kimberly Young | Research Scientist | Team |
Complete people profiles for Proteomics International
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Proteomics International
Proteomics International is a publicly listed company on the ASX with ticker symbol PIQ in Australia, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date16 Apr 2015
- Listed onASX: PIQ
- Listed entityPROTEOMICS INTERNATIONAL LABORATORIES LTD
- Exchange sectorHealth services
- ISINAU000000PIQ0
- Share price0.12 AUD (+4.17% on the day) · 2026-10-09
- Market capitalisation20,671,638.00 AUD
- Volume (last session)128,239
Financials of Proteomics International
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2026 | 278,010 AUD | -8.6M AUD | -11.1M AUD |
| 2025 | 587,390 AUD | -8.1M AUD | -10.4M AUD |
| 2024 | 892,140 AUD | -6.4M AUD | -8.2M AUD |
| 2023 | 730,340 AUD | -6.2M AUD | -7.7M AUD |
| 2022 | 1.5M AUD | -5.0M AUD | -6.3M AUD |
Detailed financial statements for Proteomics International
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Proteomics International
4 dated milestones of Proteomics International across 23 years, from founding to its latest funding, stage changes and deals.
- Founded Proteomics International is founded.
- Funding First funding round of $1.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $4.3M.
Competitors of Proteomics International
Proteomics International operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Metabolon, Maze Therapeutics, Alector, Seer and Tango Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| metabolon.com | 2000 | Morrisville, United States | $165.87M | 189 | Solutions for biomarker discovery and diagnostic testing are provided. | |
| mazetx.com | 2018 | Redwood, United States | $496M | 111 | Genetic biomarkers are developed for neurological, metabolic, and renal diseases. | |
| alector.com | 2013 | San Francisco, United States | $214.78M | 211 | Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | |
| seer.bio | 2017 | San Francisco, United States | $127.5M | 89 | Proteomics platform developed for early cancer and neurological disease detection. | |
| tangotx.com | 2017 | Cambridge, United States | $165M | 140 | Novel cancer drugs are developed using synthetic lethality screening. | |
| neophore.com | 2017 | Cambridge, United Kingdom | $44.56M | 10 | NeoPhore is focused on cancer neoantigen evolution therapies. | |
| viomelifesciences.com | 2016 | Bothell, United States | $92.44M | 136 | Provider of tests to prevent, treat, and cure chronic diseases, and cancer | |
| scailyte.com | 2017 | Lucerne, Switzerland | $20.26M | – | Single-cell data is analyzed via AI for biomarker discovery. | |
| lexpharma.com | 1995 | United States | $165M | 135 | Small molecule drugs for various therapeutic areas are developed. | |
| denovobiopharma.com | 2013 | San Diego, United States | $171.82M | 42 | Genomic biomarker discovery platform is developed for drug personalization. |
Detailed competitors of Proteomics International
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Proteomics International
The website of Proteomics International (proteomics.com.au) receives about 6K visits a month.
- Monthly visits6K
▲ 1.6% vs previous month
Websites whose visitors overlap most with Proteomics International. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
pfind.ict.ac.cn | pfind.ict.ac.cn | 100% | – | – | – |
biosoftsolutions.de | biosoftsolutions.de | 100% | – | – | – |
peptide.nist.gov | peptide.nist.gov | 100% | – | – | – |
| sbw.fi | 100% | – | – | View details | |
pan.stanford.edu | pan.stanford.edu | 99% | – | – | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for Proteomics International
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Proteomics International
Complete news archive for Proteomics International
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Proteomics International
10 companies that operate in the same segment as Proteomics International (Diabetes), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of devices for continuous glucose monitoring and manual insulin delivery | 2008 | San Diego, California, United States | USD 100.73 M | USD 1.02 B | 2,650 | |
Wearable glucose monitoring patches are provided for real-time data tracking. | 1999 | San Diego, California, United States | USD 52.5 M | USD 4.66 B | 10,300 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Small molecule drugs for various therapeutic areas are developed. | 1995 | United States | USD 165 M | USD 49.8 M | 103 | |
Implantable continuous glucose monitoring systems are provided for diabetes management. | 1996 | Germantown, United States | USD 175.46 M | USD 22.47 M | 117 | |
Developer of a closed-loop automated insulin delivery system | 2014 | Milpitas, California, United States | USD 214.51 M | – | 133 | |
Provider of workforce healthcare solutions | 2015 | New York, New York, United States | USD 107.87 M | – | 166 | |
Diabetes care and reversal programs are provided to patients. | 2021 | Bengaluru, Karnataka, India | USD 26.7 M | USD 5.07 M | 677 | |
Provider of smart devices for diabetes management for patients and doctors | 2014 | San Francisco, California, United States | USD 245.2 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 194 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Proteomics International
Proteomics International was founded in 2001 and raised its 1st funding round 11 years after it was founded.
Proteomics International is headquartered in Perth, Australia. It is registered at Perth, Western Australia, Australia.
Annual revenue of Proteomics International is $191.47K as on Jun 30, 2026.
Medical technology company at the forefront of predictive diagnostics and bio-analytical services. The company develop and commercializes diagnostic tests known as PromarkerD, for the detection of diabetic kidney disease. Company specialises in the area of proteomics, the industrial scale study of the structure and function of proteins. It also, offers analytical services for research purposes. The technology can be used to identify fingerprints from any biological source, from wheat seeds to human serum.
Proteomics International's top competitors include Alector, Lexicon Pharmaceuticals and Maze Therapeutics.
Proteomics International offers PromarkerD, PromarkerEndo, PromarkerEso, and OxiDx.
Yes, Proteomics International is publicly traded on ASX under the ticker symbol PIQ.
Proteomics International has 1 investor. Key investors include MTPConnect.